Hope4ATRT_Logo_small.png

Open Clinical Trials

Nivolumab-Ipiliumab: Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

Purpose of this clinical trial:

The main purpose of this study is to determine the safety and effectiveness of nivolumab and ipilimumab for patients with relapsed or refractory INI1- negative tumors.  Patients with multiple types of solid tumors and brain tumors will be included as part of this study.  Patients will only be eligible for this study if their tumor has shown a mutation/deletion of a gene that is known to suppress tumor growth called INI1.

Methotrexate and Etoposide Infusions Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Brain Tumors

Purpose of this clinical trial:

The goal of this clinical research study is to establish the safety of simultaneous infusions of methotrexate and etoposide into the fourth ventricle of the brain or resection cavity in patients with recurrent malignant posterior fossa brain tumors. Patients' disease must have originated in the posterior fossa of the brain.

MV-NIS: Modified Measles Virus for Children and Young Adults with Recurrent ATRT

Purpose of this clinical trial:

The main purpose of MV-NIS is to study the effects of the safety and appropriate dose level of the modified measles virus (MV-NIS) in children and young adults with recurrent (disease has returned) medulloblastoma or ATRT

PBTC-051: Phase I Study of APX005M in Pediatric CNS Tumors

Purpose of this clinical trial:

The main purpose of this study is to determine the best dose and side effects of a new drug called APX005M in treating children and young adult patients with brain cancer that is growing, spreading or getting worse.

PBTC-050: Phase I Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors

Purpose of this clinical trial:

The main purpose of this study is to determine the best dose and side effects of a combination of drugs and to see how well the work in treating children and young adults with brain cancer that has come back or did not respond to treatment. These drugs may stop the growth of tumor cells by inhibiting the enzymes needed for the cells to grow. Giving ribociclib and everolimus together may work better in treating these aggressive types of brain tumors.

SJATRT: Phase II Study of Alisertib Therapy for Rhabdoid Tumors

Sponsor Site Principal Investigator:

Santhosh Upadhyaya, MD

Phone: 901-595-5175

Email: santhosh.upadhyaya@stjude.org


Sponsor Site Coordinator:

Tabatha Doyle, RM

Phone: 901-595-2544

Email: tabatha.doyle@stjude.org

SJDAWN: Phase I Study of Molecularly-Driven Doublet Therapies

Sponsor Site Principal Investigator:

Giles Robinson, MD

Phone: 901-595-4055

Email: giles.robinson@stjude.org


Sponsor Site Coordinator:

Tabatha Doyle, RM

Phone: 901-595-2544

Email: tabatha.doyle@stjude.org

BrainChild-01: HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors

Purpose of this clinical trial:

The main purpose of this study is to determine the side effects and best dose of HER2-specific chimeric antigen receptor (CAR) T cell immunotherapy in treating patients with brain tumors that have come back or does not respond to treatment (recurrent or refractory disease).

BrainChild-02: EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors

Purpose of this clinical trial:

The main purpose of this study is to determine if T-cell therapy is safe to give to children and young adults with recurrent (disease has returned) or refractory EGFR positive central nervous system (CNS) tumors, including ATRT, and what dose of this therapy is best.

BrainChild-03: Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors

Purpose of this clinical trial:

The main purpose of this study is to determine the safety and feasibility of B7H3-specific chimeric antigen receptor (CAR) T cell immunotherapy in treating patients with brain tumors that have come back or does not respond to treatment (recurrent or refractory disease).

Auto Transplant for High Risk or Relapsed Solid or CNS Tumors

Purpose of this clinical trial:

This is a standard of care treatment guideline for high risk or relapsed solid tumors or CNS tumors consisting of a busulfan, melphalan, thiotepa conditioning (for solid tumors) or carboplatin and thiotepa conditioning (for CNS tumors) followed by an autologous peripheral blood stem cell transplant.

PVSRIPO: Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children

Purpose of this clinical trial:

The main purpose of PVSRIPO is to study the safety and appropriate dose level of the oncolytic poliovirus (PV) immunotherapy with PVSRIPO) in children and young adults with recurrent (disease has returned) grade IV ATRT.

Tazemetostat: A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

Purpose of this clinical trial:

The main purpose of this study is to establish the safety and best possible dose of tazemetostat for patients with relapsed or refractory INI1- negative tumors or synovial sarcoma.

Panobinostat: A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT (NORTH)

Purpose of this clinical trial:

This is an open label, phase II, multi-centre study evaluating the anti-tumor activity of continuous, low dose of panobinostat in patients with recurrent or refractory solid tumors stratified by primary histology into osteosarcoma, malignant rhabdoid tumor/atypical teratoid rhabdoid tumor (MRT/ATRT), and neuroblastoma.

MEMMAT: Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma and ATRT

Purpose of this clinical trial:

The goal of this study is to provide additional therapy options for children with recurrent or progressive medulloblastoma, ependymoma and ATRT, for whom no known curative therapy exists, by prolonging survival while maintaining good quality of life. The primary objective of the MEMMAT trial is to evaluate the activity of this multidrug antiangiogenic approach in previously treated children and young adults

Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain

Purpose of this clinical trial:

This phase I trial investigates the side effects and effectiveness of chemotherapy followed by a donor (allogeneic) stem cell transplant when given to patients with high grade brain cancer.

Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors

Purpose of this clinical trial:

The main purpose of this study is to establish the safety, defined by the adverse events, of B7H3-specific CAR T cell infusions delivered by a central nervous system (CNS) catheter into the tumor resection cavity or ventricular system

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

Purpose of this clinical trial:

This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested.

9-ING-41 in Pediatric Patients With Refractory Malignancies

Purpose of this clinical trial:

9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients. This Phase 1 study will study its efficacy in pediatric patients with advanced malignancies.

CLOVER-2: Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma

Purpose of this clinical trial:

The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain tumors for which there are no standard treatment options with curative potential.